Short Interest in Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Decreases By 70.7%

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the target of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 44,900 shares, a decrease of 70.7% from the January 15th total of 153,000 shares. Based on an average daily volume of 427,600 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.7% of the shares of the stock are short sold.

Protagenic Therapeutics Stock Performance

Protagenic Therapeutics stock traded up $0.00 during trading hours on Wednesday, hitting $0.27. 136,700 shares of the stock were exchanged, compared to its average volume of 462,767. Protagenic Therapeutics has a 12 month low of $0.25 and a 12 month high of $1.87. The business’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.58. The stock has a market capitalization of $1.95 million, a P/E ratio of -0.21 and a beta of 0.25.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.